High-Sensitivity Troponin I Explored Post-Cardiac Surgery

By LabMedica International staff writers
Posted on 07 Mar 2022

Image: The Architect STAT Troponin-I assay is a 2-step chemiluminescent microparticle immunoassay designed to detect cardiac troponin I (cTnI) in serum and plasma using the ARCHITECT i2000SR immunoassay analyzer (Photo courtesy of Abbott Diagnostics)

Consensus recommendations regarding the threshold levels of cardiac troponin elevations for the definition of perioperative myocardial infarction and clinically important periprocedural myocardial injury in patients undergoing cardiac surgery range widely.

Although cardiac surgery has the potential to improve the quality and prolong the duration of a patient’s life, it is associated with complications. Prognostically important myocardial injury, detected by an elevated concentration of either cardiac troponin or creatine kinase MB4, is one of the most common complications after cardiac surgery and is associated with increased mortality.

A large international team of clinical scientists led by those from McMaster University (Hamilton, ON, USA) recruited patients from a convenience sample of 24 hospitals in 12 countries from May 2013 through April 2019. Patients were enrolled from North America (35.9%), Asia (28.3%), Europe (26.2%), South America (6.3%), and Australia (3.3%). The mean age of the study cohort was 63.3 years, 70.9% of the patients were men, 29.3% had a history of myocardial infarction, and 70.2% were White. Blood samples were obtained for measurement of cardiac troponin I levels with the ARCHITECT STAT assay (Abbott Laboratories, Abbott Park, IL, USA), (upper reference limit, 26 ng/L; limit of detection, 1 to 2 ng/L liter) before surgery, 3 to 12 hours after surgery, and on days 1, 2, and 3 after surgery.

The team reported that within the first day after surgery, troponin was measured in 13,662 patients. Among these patients, 13,316 patients (97.5%) had a peak troponin measurement of more than 260 ng/L (>10 times the upper reference limit), 12,217 patients (89.4%) had a peak troponin measurement of at least 910/L (≥35 times the upper reference limit), and 10,205 patients (74.7%) had a peak troponin measurement of at least 1,820 ng/L (≥70 times the upper reference limit). By 30 days after surgery, 296 patients (2.1%) had died and 399 patients (2.9%) had had a major vascular complication. Among patients who underwent other cardiac surgery, the corresponding threshold troponin level was 12,981 ng/L (95% CI, 2673 to 16,591), a level 499 times the upper reference limit.

The authors concluded that the levels of high-sensitivity troponin I after cardiac surgery that were associated with an increased risk of death within 30 days were substantially higher than levels currently recommended to define clinically important periprocedural myocardial injury. The study was published on March 3, 2022 in the journal The New England Journal of Medicine.

Related Links:
McMaster University
Abbott Laboratories